apl. Prof. Dr. Peter Goebell

Medizinische Fakultät Urologische Klinik

Editorial: Cutting edge basic and clinical bladder cancer research – the IBCN updates (2023) Goebell P, Kamat AM, Black PC, Dyrskjøt L, Nawroth R, Seiler R, Todenhöfer T, et al. Journal article, Review article Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study) (2022) Zeuschner P, Hoelters S, Stoeckle M, Seliger B, Mueller A, Bachmann HS, Gruenwald V, et al. Conference contribution Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT (2022) Goebell P, Gruellich C, Mueller L, Boegemann M, Martens U, Von Der Heyde E, Reichert D, et al. Conference contribution A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (Everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study of the IAG-N) (2022) Hilser T, Gruenwald V, Bergmann L, Goebell P, Strauss A, Meiler J, Hartmann A, et al. Conference contribution Prognostic potential of baseline HRQoL in advanced and metastatic renal cell carcinoma (2022) Gruenwald V, Goebell P, Schostak M, Welslau M, Doehn C, Degenkolbe E, Ehness R, et al. Conference contribution Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients (2022) Lieb V, Abdulrahman A, Weigelt K, Hauch S, Gombert M, Guzman J, Bellut L, et al. Journal article The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape (2022) Doehn C, Bögemann M, Grünwald V, Welslau M, Bedke J, Schostak M, Wolf T, et al. Journal article Treatment of patients with advanced urothelial carcinoma in routine care in Germany: initial data from the CARAT-UBC cohort (2022) Goebell P, Mueller L, Boegemann M, Rauh J, Nusch A, Andres-Pons A, Hamm N, et al. Conference contribution Drug Therapy Safety with new oral Antitumor Agents for the Therapy of Prostate and Renal Cell Carcinoma: Findings from the AMBORA Study (2022) Cuba L, Schlichtig K, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Conference contribution New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial (2022) Schlichtig K, Cuba L, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Journal article